Advertisement

Journal of Neuro-Oncology

, Volume 112, Issue 1, pp 49–57 | Cite as

EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry

  • Isabelle Cornez
  • Mrinal Joel
  • Kjetil Taskén
  • Iver A. Langmoen
  • Joel C. Glover
  • Torunn Berge
Laboratory Investigation

Abstract

Development of novel patient stratification tools for cancer is a challenge that require advanced molecular screening and a detailed understanding of tumour signalling networks. Here, we apply phospho-specific flow cytometry for signal profiling of primary glioblastoma tumours after preservation of single-cell phosphorylation status as a strategy for evaluation of tumour signalling potential and assessment of rapamycin-mediated mTOR inhibition. The method has already enhanced insight into cancers and disorders of the immune system, and our study demonstrate a great potential to improve the understanding of aberrant signalling in glioblastoma and other solid tumours.

Keywords

EGF signalling Glioblastoma multiforme Phosphoflow cytometry Rapamycin 

Notes

Acknowledgments

The authors wish to thank Jorun Solheim for work on sequencing of the tumour samples. The work was supported by grants from the Norwegian Cancer Society, South-Eastern Regional Health Authority and the Research Council of Norway.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

11060_2012_1035_MOESM1_ESM.docx (804 kb)
Supplementary material 1 (DOCX 804 kb)

References

  1. 1.
    Akhavan D, Cloughesy TF, Mischel PS (2010) mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 12:882–889PubMedCrossRefGoogle Scholar
  2. 2.
    Benito R, Gil-Benso R, Quilis V, Perez M, Gregori-Romero M, Roldan P, Gonzalez-Darder J, Cerda-Nicolas M, Lopez-Gines C (2010) Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Neuropathology 30:392–400PubMedCrossRefGoogle Scholar
  3. 3.
    Chalhoub N, Baker SJ (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4:127–150PubMedCrossRefGoogle Scholar
  4. 4.
    Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  5. 5.
    Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8PubMedCrossRefGoogle Scholar
  6. 6.
    Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320PubMedGoogle Scholar
  7. 7.
    Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology and paths to treatment. Genes Dev 21:2683–2710PubMedCrossRefGoogle Scholar
  8. 8.
    Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS, Riggins GJ (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4:709–714PubMedCrossRefGoogle Scholar
  9. 9.
    Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2:e24CrossRefGoogle Scholar
  10. 10.
    Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, Adamson DC (2009) Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets 13:701–718PubMedCrossRefGoogle Scholar
  11. 11.
    Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE (2009) A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92:99–105PubMedCrossRefGoogle Scholar
  12. 12.
    Krutzik PO, Clutter MR, Trejo A, Nolan GP (2011) Fluorescent cell barcoding for multiplex flow cytometry. Curr Protoc Cytom. doi: 10.1002/0471142956.cy0631s55
  13. 13.
    Krutzik PO, Nolan GP (2006) Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 3:361–368PubMedCrossRefGoogle Scholar
  14. 14.
    Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77:400–410PubMedCrossRefGoogle Scholar
  15. 15.
    Masui K, Cloughesy TF, Mischel PS (2012) Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 38:271–291PubMedCrossRefGoogle Scholar
  16. 16.
    Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedCrossRefGoogle Scholar
  17. 17.
    Merlo V, Longo M, Novello S, Scagliotti GV (2011) EGFR pathway in advanced non-small cell lung cancer. Front Biosci (Schol Ed) 3:501–517CrossRefGoogle Scholar
  18. 18.
    Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224PubMedCrossRefGoogle Scholar
  19. 19.
    Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF (2003) Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22:2361–2373PubMedCrossRefGoogle Scholar
  20. 20.
    Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8:711–719PubMedCrossRefGoogle Scholar
  21. 21.
    Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G (2004) S6K1(−/−)/S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24:3112–3124PubMedCrossRefGoogle Scholar
  22. 22.
    Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ± mice. Proc Natl Acad Sci USA 98:10320–10325PubMedCrossRefGoogle Scholar
  23. 23.
    Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, Stupp R (2011) Current concepts and management of glioblastoma. Ann Neurol 70:9–21PubMedCrossRefGoogle Scholar
  24. 24.
    Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027–5034PubMedGoogle Scholar
  25. 25.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  26. 26.
    Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602–8606PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Isabelle Cornez
    • 1
    • 7
  • Mrinal Joel
    • 2
    • 3
    • 4
  • Kjetil Taskén
    • 1
    • 5
  • Iver A. Langmoen
    • 2
    • 4
    • 6
  • Joel C. Glover
    • 3
    • 4
  • Torunn Berge
    • 1
  1. 1.The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of OsloOsloNorway
  2. 2.Vilhelm Magnus Laboratory for Neurosurgical ResearchInstitute for Surgical Research, Oslo University HospitalOsloNorway
  3. 3.Department of PhysiologyInstitute of Basic Medical Sciences, University of OsloOsloNorway
  4. 4.Norwegian Center for Stem Cell ResearchOsloNorway
  5. 5.Department of Infectious DiseasesOslo University HospitalOsloNorway
  6. 6.Department of NeurosurgeryOslo University HospitalOsloNorway
  7. 7.Biomedizinisches Zentrum (BMZ), Medizinische Klinik IIIBonnGermany

Personalised recommendations